<DOC>
	<DOCNO>NCT02768207</DOCNO>
	<brief_summary>This single arm , multicenter , open label , non-randomized clinical study adult participant unresectable metastatic melanoma . The study conduct two phase . Pre-screening phase ass BRAF V600 mutation new mutation analysis trigger mutant plasma cfDNA test result . Treatment phase assess clinical outcome participant treat vemurafenib plus cobimetinib . The length study approximately 36 month .</brief_summary>
	<brief_title>A Study Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 ( BRAF ) V600 Mutation Cell-Free Deoxyribonucleic Acid ( cfDNA ) From Plasma Participants With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Prescreening phase : Participants histologically confirm melanoma , either unresectable Stage IIIc Stage IV metastatic melanoma , define American Joint Committee Cancer ( AJCC ) 7th edition Documentation BRAF V600 test result mutationpositive status melanoma tumor tissue use validated tissue test Treatment Phase : Eastern cooperative oncology group ( ECOG ) performance status 02 Adequate hematologic end organ function obtain within 14 day prior first dose study drug treatment Negative serum pregnancy test prior commencement dose woman childbearing potential Absence psychological , familial , sociological , geographical condition potentially hamper compliance study protocol treatment regimen followup treatment discontinuation schedule Female participant childbearing potential male participant partner childbearing potential must agree always use 2 effective form contraception course study least 3 month completion study therapy Participants able swallow tablet Documentation BRAF mutation positive status melanoma tissue ( archival new ) Treatment Phase : History prior rapidly accelerate fibrosarcoma ( RAF ) mitogenactivated protein kinase ( MEK ) pathway inhibitor treatment Palliative radiotherapy within 14 day prior first dose study treatment Evidence retinal pathology ophthalmologic examination Systemic risk factor retinal vein occlusion ( RVO ) History clinically significant cardiac dysfunction Current severe , uncontrolled systemic disease Pregnancy , lactate breast feed Intake potent cytochrome P450 3A4 ( CYP3A4 ) enzyme inducer potent CYP3A4 enzyme inhibitor least 7 day prior initiation study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>